Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options.
about
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patientsT2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasisHospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data.Cost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses.Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study.Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcomeFactors predicting prolonged empirical antifungal treatment in critically ill patients.Antifungal stewardship in daily practice and health economic implications.Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis.Is a biomarker-based diagnostic strategy for invasive aspergillosis cost effective in high-risk haematology patients?The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).Antifungal Activity of SCY-078 and Standard Antifungal Agents Against 178 Clinical Isolates of Resistant and Susceptible Candida Species.Cross-resistance between voriconazole and fluconazole for non-albicans Candida infection: a case-case-control study.Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients.Invasive fungal infection after heart transplantation: A 7-year, single-center experience."Is there an emerging need for new antifungals?".Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK.Current challenges of research on filamentous fungi in relation to human welfare and a sustainable bio-economy: a white paper.Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.[Epidemiological transition of mycosis diseases in sub-Saharan Africa: from surface to depth].Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis.Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids.Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
P2860
Q24186457-CC0A5AEE-2C1D-484C-84C9-710CA8E9B044Q28084998-EF57D37F-340D-4076-A8FB-289F1D5E6815Q30829283-EB0F2B85-BA26-4C58-B110-B82926503922Q36056617-D82B4AD0-837B-4D2D-852F-446300EF5FDEQ36209069-2CAD72BC-092A-460E-84AD-920E5121ED93Q37287794-F699DE54-90A1-4675-8650-5AA4C5F0EF1BQ37699716-76E8B8C6-D706-43CC-8276-313389C8D204Q38511950-6E31935C-BCFB-4F83-B515-C340AFC7CF38Q38589279-55C0E553-1036-4CEA-97EA-82D3524D8598Q38993519-079D79A2-9039-4D0A-A0B0-298149257A0EQ39189670-81BED05F-62CD-4EF7-B31E-7572AC444B5AQ40085154-9919D77D-7957-4B6A-9133-7FA7EF4EFF54Q40169961-BB79CC40-19C9-4536-BAFD-9009EA3ADCD2Q40377329-68AB2347-1CC7-4681-A228-A4C37B38BD55Q40413402-9FBBE956-0C79-4A96-BFC6-71DC62A8089CQ40788985-1FCF8CAD-2814-499A-81D4-84FE2EECAFBEQ41656144-65975B05-8301-4C79-8A91-F3AEDE9CD71DQ42363293-A0B32D6A-413C-4E38-8397-66E18272A268Q44482692-479A3C8A-5B49-4182-A3A3-76D5EDBCCCA4Q45227105-347AB530-BA3B-43D3-B0FC-84AA1A6F61DDQ49379463-43CB3C23-5A2D-4868-955F-7D1362CA0DD0Q52673294-0A96A0C4-4272-49FD-AB4C-2E5E9A99B455Q58701180-847878E5-ADAD-4907-B1B5-7F23A5E5378E
P2860
Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Cost of invasive fungal infect ...... nd expanded treatment options.
@en
Cost of invasive fungal infect ...... nd expanded treatment options.
@nl
type
label
Cost of invasive fungal infect ...... nd expanded treatment options.
@en
Cost of invasive fungal infect ...... nd expanded treatment options.
@nl
prefLabel
Cost of invasive fungal infect ...... nd expanded treatment options.
@en
Cost of invasive fungal infect ...... nd expanded treatment options.
@nl
P2093
P2860
P1433
P1476
Cost of invasive fungal infect ...... nd expanded treatment options.
@en
P2093
Barbara Alexander
Dominika Dabrowski
George Papadopoulos
Manishi Prasad
Melissa Johnson
Richard Drew
Robert Danna
Valery Walker
P2860
P304
P356
10.1002/J.1875-9114.2012.01124
P407
P577
2012-10-01T00:00:00Z